Search research articles
Contact Us
Filters
Showing results (191-200 of 304) with videos related to
Page
of 31
Sort By:
Breast Cancer Research and Treatment
|
April 16, 1998
Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response
A Makris, T J Powles, D C Allred, et al.
Clinical Endocrinology
|
February 1, 1985
Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer
R Stuart-Harris, M Dowsett, A D'Souza, et al.
Breast Cancer Research and Treatment
|
December 25, 2003
Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer
L Assersohn, J Salter, T J Powles, et al.
Cancer Research
|
May 15, 1989
Intratumoral aromatase as a prognostic factor in human breast carcinoma
M C Silva, M G Rowlands, M Dowsett, et al.
Lancet (London, England)
|
July 22, 1998
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
T Powles, R Eeles, S Ashley, et al.
The Journal of Steroid Biochemistry and Molecular Biology
|
March 1, 1993
Control of aromatase in breast cancer cells and its importance for tumor growth
M Dowsett, V Macaulay, J Gledhill, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1992
An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients
M Dowsett, A Mehta, N King, et al.
Cancer Research
|
March 1, 1990
Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A
R C Stein, M Dowsett, J Davenport, et al.
British Journal of Cancer
|
April 26, 2012
Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer
S Barton, L Zabaglo, R A'Hern, et al.
Journal of Enzyme Inhibition
|
January 1, 1992
Effects of 4-hydroxyandrost-4-ene-3,17-dione and its metabolites on 5 alpha-reductase activity and the androgen receptor
J H Davies, R J Shearer, M G Rowlands, et al.
Page
of 31
Search research articles
Search
Showing results (191-200 of 304) with videos related to
Sort By:
Page
of 31
Breast Cancer Research and Treatment
|
April 16, 1998
Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response
A Makris, T J Powles, D C Allred, et al.
Clinical Endocrinology
|
February 1, 1985
Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer
R Stuart-Harris, M Dowsett, A D'Souza, et al.
Breast Cancer Research and Treatment
|
December 25, 2003
Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer
L Assersohn, J Salter, T J Powles, et al.
Cancer Research
|
May 15, 1989
Intratumoral aromatase as a prognostic factor in human breast carcinoma
M C Silva, M G Rowlands, M Dowsett, et al.
Lancet (London, England)
|
July 22, 1998
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
T Powles, R Eeles, S Ashley, et al.
The Journal of Steroid Biochemistry and Molecular Biology
|
March 1, 1993
Control of aromatase in breast cancer cells and its importance for tumor growth
M Dowsett, V Macaulay, J Gledhill, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1992
An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients
M Dowsett, A Mehta, N King, et al.
Cancer Research
|
March 1, 1990
Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A
R C Stein, M Dowsett, J Davenport, et al.
British Journal of Cancer
|
April 26, 2012
Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer
S Barton, L Zabaglo, R A'Hern, et al.
Journal of Enzyme Inhibition
|
January 1, 1992
Effects of 4-hydroxyandrost-4-ene-3,17-dione and its metabolites on 5 alpha-reductase activity and the androgen receptor
J H Davies, R J Shearer, M G Rowlands, et al.
Page
of 31